Your browser doesn't support javascript.
loading
Measurement of ex vivo resistance to proteasome inhibitors, IMiDs, and daratumumab during multiple myeloma progression.
Walker, Zachary J; VanWyngarden, Michael J; Stevens, Brett M; Abbott, Diana; Hammes, Andrew; Langouët-Astrie, Christophe; Smith, Clayton A; Palmer, Brent E; Forsberg, Peter A; Mark, Tomer M; Jordan, Craig T; Sherbenou, Daniel W.
Afiliação
  • Walker ZJ; Division of Hematology, Department of Medicine.
  • VanWyngarden MJ; Division of Hematology, Department of Medicine.
  • Stevens BM; Division of Hematology, Department of Medicine.
  • Abbott D; Center for Innovative Design and Analysis, Department of Biostatistics and Informatics, Colorado School of Public Health.
  • Hammes A; Center for Innovative Design and Analysis, Department of Biostatistics and Informatics, Colorado School of Public Health.
  • Langouët-Astrie C; Division of Hematology, Department of Medicine.
  • Smith CA; Division of Hematology, Department of Medicine.
  • Palmer BE; Division of Allergy and Clinical Immunology, ClinImmune Labs, and.
  • Forsberg PA; Division of Allergy and Clinical Immunology, ClinImmune Labs, and.
  • Mark TM; University of Colorado Cancer Center, University of Colorado Anschutz Medical Campus, Aurora, CO.
  • Jordan CT; Division of Hematology, Department of Medicine.
  • Sherbenou DW; Division of Hematology, Department of Medicine.
Blood Adv ; 4(8): 1628-1639, 2020 04 28.
Article em En | MEDLINE | ID: mdl-32311014

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Mieloma Múltiplo Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Blood Adv Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Mieloma Múltiplo Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Blood Adv Ano de publicação: 2020 Tipo de documento: Article